Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients

Authors:

Abstract
No abstract available
Funding Information
  • Merck Sharp and Dohme France
  • Pfizer
  • UCB